Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Torré Anderson, II, Fourth Year Doctor of Pharmacy Candidate, Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health Ashley Ball, PharmD Candidate, LECOM-School of Pharmacy Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy Anina Pham, PharmD. Candidate, Lake Erie College of Osteopathic Medicine, College of Pharmacy Jessica Rogers, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences | 
The number of GLP1-RA’s has grown over the past few years, and the fact that there are still new ones working their way towards approval can be viewed as a measuring stick to how important this class will be for treating diabetes now and going forward. Each time a new class member comes out, the manufacturer is forced to find a way to differentiate itself from the rest of the class. This could be as simple as a better delivery device, or looking for new benefits in patient care. This week our intern Alan Martinez, PharmD Candidate, USF College of Pharmacy, takes a look at